265,283 Shares in Merck & Co., Inc. (NYSE:MRK) Purchased by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR bought a new position in shares of Merck & Co., Inc. (NYSE:MRKFree Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 265,283 shares of the company’s stock, valued at approximately $26,390,000. Merck & Co., Inc. makes up 0.7% of Generali Asset Management SPA SGR’s holdings, making the stock its 24th biggest holding.

A number of other institutional investors have also added to or reduced their stakes in the company. Tradewinds LLC. grew its position in Merck & Co., Inc. by 0.6% during the third quarter. Tradewinds LLC. now owns 15,649 shares of the company’s stock worth $1,777,000 after buying an additional 101 shares in the last quarter. CGN Advisors LLC boosted its holdings in Merck & Co., Inc. by 0.4% during the fourth quarter. CGN Advisors LLC now owns 26,969 shares of the company’s stock valued at $2,683,000 after purchasing an additional 102 shares in the last quarter. Cypress Wealth Services LLC boosted its holdings in Merck & Co., Inc. by 3.1% during the fourth quarter. Cypress Wealth Services LLC now owns 3,639 shares of the company’s stock valued at $362,000 after purchasing an additional 111 shares in the last quarter. TI Trust Inc. boosted its holdings in Merck & Co., Inc. by 0.6% during the fourth quarter. TI Trust Inc. now owns 19,834 shares of the company’s stock valued at $1,973,000 after purchasing an additional 111 shares in the last quarter. Finally, Hengehold Capital Management LLC boosted its holdings in Merck & Co., Inc. by 0.3% during the fourth quarter. Hengehold Capital Management LLC now owns 39,989 shares of the company’s stock valued at $3,978,000 after purchasing an additional 112 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Up 0.3 %

Merck & Co., Inc. stock opened at $94.84 on Tuesday. The firm has a 50-day moving average of $93.47 and a 200-day moving average of $101.62. Merck & Co., Inc. has a one year low of $81.04 and a one year high of $134.63. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The company has a market cap of $239.56 billion, a price-to-earnings ratio of 14.09, a P/E/G ratio of 0.77 and a beta of 0.35.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Tuesday, February 4th. The company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.13). The firm had revenue of $15.62 billion during the quarter, compared to the consensus estimate of $15.51 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The firm’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.03 earnings per share. On average, equities analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be issued a dividend of $0.81 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $3.24 annualized dividend and a dividend yield of 3.42%. Merck & Co., Inc.’s dividend payout ratio is presently 48.14%.

Merck & Co., Inc. announced that its board has initiated a stock buyback program on Tuesday, January 28th that permits the company to buyback $10.00 billion in outstanding shares. This buyback authorization permits the company to reacquire up to 4.1% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MRK. Deutsche Bank Aktiengesellschaft downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their target price for the stock from $128.00 to $105.00 in a report on Tuesday, February 18th. Truist Financial reissued a “hold” rating and issued a $110.00 target price (down from $130.00) on shares of Merck & Co., Inc. in a report on Wednesday, January 8th. BMO Capital Markets reduced their target price on Merck & Co., Inc. from $105.00 to $96.00 and set a “market perform” rating on the stock in a report on Wednesday, February 5th. TD Securities cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $121.00 to $100.00 in a research report on Monday, February 10th. Finally, TD Cowen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $121.00 to $100.00 in a research report on Monday, February 10th. Eleven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $117.12.

Check Out Our Latest Analysis on MRK

Insider Transactions at Merck & Co., Inc.

In related news, insider Cristal N. Downing sold 2,361 shares of the stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $88.76, for a total transaction of $209,562.36. Following the sale, the insider now owns 7,085 shares in the company, valued at approximately $628,864.60. This trade represents a 24.99 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Inge G. Thulin purchased 2,833 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, February 6th. The shares were purchased at an average price of $88.25 per share, for a total transaction of $250,012.25. Following the transaction, the director now directly owns 2,933 shares in the company, valued at $258,837.25. This represents a 2,833.00 % increase in their position. The disclosure for this purchase can be found here. Insiders own 0.09% of the company’s stock.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Featured Articles

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.